CMPS News and Press, COMPASS Pathways Plc

2026-07-09 10:30:03 ET Wolfe Research analyst issues BUY recommendation for CMPS on July 9, 2026 01:48PM ET. The previous analyst recommendation was Buy. CMPS was trading at $13.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2026-07-08 13:23:52 ET The last time I spoke about Compass Pathways plc ( CMPS ), it was with a Seeking Alpha article entitled " Compass Pathways: Maintain Hold Rating With COMP360 Going Beyond TRD Development ." With respect to this article, I already mentioned that the com...

2026-07-08 12:28:38 ET More on COMPASS Pathways ADS Compass Pathways Phase 3 COMP006 Data Review COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript Compass Pathways: A Psychedel...

2026-07-07 18:15:07 ET Paul Matteis from Stifel Nicolaus issued a price target of $21.00 for CMPS on 2026-07-07 20:33:00. The adjusted price target was set to $21.00. At the time of the announcement, CMPS was trading at $12.99. The overall price target consensus is at $2...

2026-07-07 17:32:28 ET COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression July 7, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: COMPASS Pathways plc (CMPS) Di...

2026-07-07 14:15:03 ET from Compass Point issued a price target of $25.00 for CMPS on 2026-07-07 16:10:00. The adjusted price target was set to $25.00. At the time of the announcement, CMPS was trading at $13.12. The overall price target consensus is at $18.57 with high ...

2026-07-07 08:59:11 ET Read the full article on Seeking Alpha For further details see: 4 stocks to watch on Tuesday: CMPS, CRM, SNPS, ADSK

2026-07-07 07:16:43 ET More on COMPASS Pathways ADS Compass Pathways: A Psychedelics Story Compass Pathways: A Trip Worth Taking Before The FDA Verdict Compass Pathways: Imminent Commercialization Should Provide Further Upside COMPASS outlines 1 to 2-month FD...

New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further validating COMP360’s differentiated profile in highly chronic TRD Across t...

2026-06-30 09:00:12 ET Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated i...